medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2015, Number 2

Next >>

Arch Neurocien 2015; 20 (2)

Comparison of quality of life in patients with progressive supranucelar palsy and Parkinson’s disease and its impact on the caregiver

León-Manríquez E, Velázquez-Osuna S, Morales-Briceño H, Calderón-Fajardo H, Llorens-Arenas R, Cervantes-Arriaga A, Rodríguez-Violante M

Language: Spanish
References: 22
Page: 99-103
PDF size: 97.49 Kb.


ABSTRACT

Objective: tod escribe and compare the quality of life of patients and caregiver burden in patients with a diagnosis of progressive supranuclear palsy (PSP) and Parkinson disease (PD) in similar stages of severity of parkinsonism. Material and methods: a cross-sectional case-control study with patients diagnosed with progressive supranuclear palsy and Parkinson’s disease patients was carried out. The scale of quality of life European Quality of Life-5 Dimensions (EQ-5D) and the EQ-VAS were applied to assess the quality of life of patients. The Zarit questionnaire was used to assess the caregiver burden. Results: a total of 13 patients with a diagnosis of probable PSP and 13 patients diagnosed with PD matched for gender and disease severity based on the Hoehn and Yahr were included. The EQ-VAS score was higher in PD patients compared to those with PSP (83.1% vs 61.5%, p = 0.03). The frequency of the caregiver burden was low in both groups. An 84.6% of the caregivers of PD patients did not show any burden, compared with 76.9% of the caregivers of patients with PSP. Conclusions: the quality of life is lower in patients with PSP compared to PD subjects in similar stages of motor severity. Perceived caregiver burden in both cases is low.


REFERENCES

  1. David R, Williams Andrew, J Lees. Progressive Supranuclear Palsy: clinico pathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270-9.

  2. Liscic RM, Srulijes K, Gröger A, Maetzler W, Berg D. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Ac Neurol Scand 2013;127:362-70.

  3. Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004;363:1783-93.

  4. Litvan I, Agid Y, Calne D. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele- Richardson-Olszewski syndrome): report of the NINDS–SPSP international workshop. Neurol 1996;47:1-9.

  5. Lin WY, Lin KJ, Weng YH. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy. Nucl Med Commun 2010; 31:974-80.

  6. Jellinger KA. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Neurodegenerative Dis 2008;5:339-46.

  7. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270-9.

  8. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010; 25:2649-53.

  9. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement disorder society task force on the hoehn and yahr staging scale: status and recommendations. Mov Disord 2004; 1020-8.

  10. Martínez-Martín P, Rodriguez-Blazquez C, lvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A. Expanded and independent validation of the Movement Disorder Society- Unified Parkinson’s disease rating scale (MDS-UPDRS). J Neurol 2013;260:228-36.

  11. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16:199-208.

  12. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 1986; 26(3):260-6.

  13. Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, Kostic VS. Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol 2014;261:1575-83.

  14. Schrag A, Selai, Quinn N, Hobart J. Measuring health-related quality of life in patients with progressive supranuclear palsy. Neurocase 2005;11:246-9.

  15. Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, et al. Measuring quality of life in PSP: the PSP-QoL. Neurol 2006; 67:39-44.

  16. Winter Y, Spottke AE, Stamelou M, Chabanel N, Eggert K, Höglinger EU, et al. Health-related quality of life in multiple system atrophy and progressive supranucelar palsy. Neurodegener Dis 2011;8:438-46.

  17. Higginson IJ, Gao SW, Saleem TZ, Chaudhuri KR, Burman R, McCrone P, et al. Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLos One 2012;7:e46327.

  18. Schrag A, Selai C, Davis J, Lees AJ, Jahanshahi M, Quinn N. Helath-related quality of life in patients with progressive supranuclear palsy. Mov Disord 2003;18:1464-9.

  19. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson’s disease: a systematic review. Mov Disord 2007;22:1528-37.

  20. Uttl B, Santacruz P, Litvan I, Grafman J. Careginving in progressive supranuclear palsy. Neurol 1998;51:1303-9.

  21. Rodríguez-Violante M, Camacho-Ordoñez A, Cervantes-Arriaga A, González-Latapi P, Velázquez-Osuna S. Factors associated with the quality of life of subjects with Parkinson’s disease and burden on their caregivers. Neurol 2014; doi: 10.1016/ j.nrl.2014.01.008.

  22. Knight BG, Sayegh P. Cultural values and caregiving: the updated sociocultural stress and coping model. J Gerontol B Psychol Sci Soc Sci 2010;65:5-13.




2020     |     www.medigraphic.com